Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data

详细信息    查看全文

• 作者：A. Loblaw^&lowast ; ; ^&dagger ; ; ^&Dagger ; ; ^{andrew.loblaw@sunnybrook.ca} ; T. Pickles^§ ; ; J. Crook^¶ ; ; A.-G. Martin^|| ; E. Vigneault^|| ; L. Souhami^&lowast ; &lowast ; ; F. Cury^&lowast ; &lowast ; ; J. Morris^§ ; ; C. Catton^&dagger ; &dagger ; ; H. Lukka^&Dagger ; &Dagger ; ; P. Cheung^&lowast ; ; ^&Dagger ; ; P. Sethukavalan^&Dagger ; ; A. Warner^§ ; § ; ; Y. Yang^§ ; § ; ; G. Rodrigues^§ ; § ; ; ^¶ ; ¶ ; ; on behalf of the Genitourinary Radiation Oncologists of Canada (GUROC)
• 关键词：Biochemical outcomes ; brachytherapy ; external beam radiotherapy ; prostate cancer ; stereotactic body radiotherapy
• 刊名：Clinical Oncology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：29
• 期：3
• 页码：161-170
• 全文大小：903 K
• 卷排序：29

文摘

Propensity-based analyses of low risk prostate cancer patients treated across Canada-wide with low dose rate brachytherapy (LDR), stereotactic body radiotherapy (SABR) or external beam radiotherapy (EBRT) are presented. There were no significant differences in biochemical failure before or after matching for SABR versus LDR although prostate-specific antigen (PSA) nadirs were lower after LDR. For the SABR versus EBRT, SABR had a biochemical failure-free survival (BFFS) trend before matching (P = 0.08), which became significant after matching (P < 0.001).